Short answer
Indivior Pharmaceuticals, Inc. (INDV) filed an 8-K current report with the SEC on October 6, 2026 reporting Item 8.01 (Other Events). Merger proxy supplement filed October 6, 2026 after stockholder demand letters and two New York lawsuits alleging disclosure deficiencies.
Indivior Pharmaceuticals, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Merger proxy supplement filed October 6, 2026 after stockholder demand letters and two New York lawsuits alleging disclosure deficiencies
- Litigation risk remains a potential source of delay, despite Indivior and Supernus denying wrongdoing and voluntarily adding disclosures
- Special stockholder meetings scheduled for October 15, 2026, making approval the immediate transaction catalyst
- Revised advisor analyses incorporate Indivior’s approximately $500 million debt and $1 billion special dividend
- Updated DCF ranges: Supernus $50.55 to $59.50 per share, Indivior $24.20 to $43.90 dividend-adjusted per share
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Indivior Pharmaceuticals, Inc. 8-K filings
Get the next INDV 8-K as it lands
Follow INDV for push alerts, or ask the research agent what this filing means.